CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of CEL-SCI (NYSE:CVM) in a research note issued on Saturday. The firm set a “sell” rating on the stock.

CEL-SCI Trading Down 0.1 %

NYSE:CVM opened at $0.24 on Friday. The stock has a fifty day simple moving average of $0.36 and a 200 day simple moving average of $0.63. The firm has a market capitalization of $19.12 million, a price-to-earnings ratio of -0.50 and a beta of 0.67. CEL-SCI has a 1-year low of $0.23 and a 1-year high of $2.39. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66.

Institutional Investors Weigh In On CEL-SCI

Several hedge funds have recently made changes to their positions in CVM. Geode Capital Management LLC grew its position in CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after purchasing an additional 53,879 shares in the last quarter. Plotkin Financial Advisors LLC acquired a new stake in shares of CEL-SCI in the third quarter worth $98,000. Finally, Thoroughbred Financial Services LLC boosted its position in shares of CEL-SCI by 40.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after buying an additional 54,900 shares during the period. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.